← Eichor
Study identifier: NCT06331052 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

3-D Tractography FUS Ablation for Essential Tremor

Condition: Essential Tremor  ·  Sponsor: University of North Carolina, Chapel Hill

PhaseNA
Planned participants24
Who can joinAll sexes, 22 Years to no upper limit
Healthy volunteersNo

About this study

The investigators propose to advance Vim-FUSA (Ventral Intermediate Nucleus - Focused Ultrasound Ablation) with the support of 3-D tractography, a neuroimaging technique to visually represent nerve tracts within the brain. The investigators hypothesize that 3-D tractography Vim-FUSA will improve the Vim ablation compared to standard Vim-FUSA and prove safe and feasible in the clinical setting. The investigators also hypothesize that intraoperative magnetic resonance (i-MR) monitoring will differentiate ablated tissue from immediate perilesional edema and accurately predict the Vim-FUSA clinical outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Vibhor Krishna, MD  ·  +1(919)-445-2410  ·  vibhor_krishna@med.unc.edu

Victoria Scott  ·  919-966-0864  ·  Victoria_Scott@med.unc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of North Carolina at Chapel HillChapel Hill, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06331052